Data completeness
0/8 — Limited
Drug data last refreshed 5h ago · AI intelligence enriched 5d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DIUTENSEN-R is an oral fixed-dose combination tablet containing methyclothiazide (a thiazide diuretic) and reserpine (an antihypertensive agent). This product is designed to treat hypertension by combining diuretic and sympatholytic mechanisms. The combination leverages complementary pharmacology to reduce blood pressure through sodium/fluid excretion and peripheral vascular resistance reduction.
Pre-Launch
Pre-launch stage presents early-career opportunity for brand building teams, though limited commercial infrastructure currently exists.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
No current job openings are linked to DIUTENSEN-R, reflecting its pre-launch stage. Career opportunities will emerge post-approval, primarily in commercial and medical affairs functions focused on market penetration in a competitive hypertension landscape.
Brand ManagerProduct Manager
Worked on DIUTENSEN-R at Bausch Health? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.